LauT-1

LauT-1 is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the cancer-testis antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). The therapy utilizes the affinity-enhanced, Human Leukocyte Antigen - A2 (HLA-A2) restricted I53F TCR, which recognizes the 157-165 epitope of the NY-ESO-1 protein. To produce LauT-1, a patient's own T lymphocytes are isolated via leukapheresis, genetically modified to express the I53F TCR, and expanded *ex vivo*. The drug is administered intravenously following a conditioning regimen of non-myeloablative lymphodepleting chemotherapy and low-dose tumor irradiation, which is intended to facilitate T-cell expansion and enhance infiltration into the tumor microenvironment. LauT-1 is primarily being investigated for the treatment of NY-ESO-1-positive advanced melanoma and various sarcomas.

Brand names

LauT-1LauT1LauT 1

Other names

NY-ESO-1-redirected T cellsNY-ESO1-redirected T cellsNY-ESO 1-redirected T cellsI53F NY-ESO-1 TCR-engineered T cellsI-53F NY-ESO-1 TCR-engineered T cellsI 53F NY-ESO-1 TCR-engineered T cellsAutologous New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor-directed T cells